Physician profile
James A Harrow
NPI 1104992411
$1,979.27
in general payments reported to CMS, 2019-2025
31 companies · $530 in 2025
The $530 reported for 2025 was more than what 79% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.61 · 2020: $41.26 · 2021: $330 · 2022: $316 · 2023: $267 · 2024: $448 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,244.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $478.31 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $306.79 | 2020-2024 | Xarelto |
| Pfizer INC. | $151.49 | 2019-2024 | |
| Corium, LLC | $109.29 | 2023-2025 | Azstarys |
| Novo Nordisk INC | $97.99 | 2022-2023 | Rybelsus, Wegovy, Ozempic |
| Indivior INC. | $95.43 | 2025 | Sublocade |
| Takeda Pharmaceuticals U.S.A., INC. | $85.66 | 2025 | Trintellix |
| Dexcom, INC. | $84.29 | 2021-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $75.99 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Amarin Pharma, INC. | $51.54 | 2019-2021 | |
| Tris Pharma INC | $38.87 | 2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $33.75 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $29.02 | 2025 | Qelbree |
| Amgen INC. | $28.61 | 2021-2023 | Repatha, Otezla |
| Philips North America LLC | $27.85 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.35 | 2020 | |
| Inogen, INC. | $23.10 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $22.21 | 2024 | |
| Inspire Medical Systems, INC. | $21.13 | 2025 | Inspire |
| Mylan Specialty L.P. | $20.82 | 2022 | |
| Abbott Laboratories | $19.31 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.89 | 2022 | |
| Acadia Pharmaceuticals INC | $18.83 | 2023 | Daybue |
| Alkermes, INC. | $17.56 | 2021 | |
| Ossur Americas, INC. | $17.45 | 2025 | |
| Ironshore Pharmaceuticals INC. | $15.82 | 2023 | Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $15.40 | 2022 | |
| Astellas Pharma US INC | $13.63 | 2023 | Cresemba |
| Phathom Pharmaceuticals, INC. | $11.64 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $11.49 | 2021 | |
| Intra-Sana Laboratories | $10.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Harrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.